Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target mRNAs with partial complementarity to CD3E shRNA guide strand refers to a class of unintended transcripts affected during RNA interference (RNAi) experiments or therapies targeting the CD3 epsilon (CD3E) gene. This phenomenon occurs when the shRNA guide strand, intended for CD3E, binds to non-target mRNAs via partial sequence homology, typically involving the 'seed' region (nucleotides 2-8) (Jackson et al., 2003). These interactions lead to the degradation or translational inhibition of the off-target mRNAs through the RNA-induced silencing complex (RISC), potentially causing cellular toxicity or confounding experimental results (Birmingham et al., 2006). In the context of CD3E, which is critical for T-cell receptor signaling and T-cell activation, off-target effects could inadvertently alter immune responses or cell viability (Sigoillot & King, 2011). Identifying these off-targets is essential for ensuring the specificity of shRNA-based tools and the safety of nucleic acid therapeutics. Researchers often use bioinformatics tools and transcriptome-wide expression profiling to predict and monitor these unintended interactions.
Sequence-specific downregulation of unintended mRNA transcripts via the RNA-induced silencing complex (RISC) due to partial sequence complementarity, primarily in the seed region (nucleotides 2-8) of the shRNA guide strand (Jackson et al., 2003; Birmingham et al., 2006).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target mRNAs with partial complementarity to CD3E shRNA guide strand (CD3E shRNA off-targets).